GenSight Biologics (SIGHT) Q4 2025 TU earnings summary

Executive summary

• Cash and cash equivalents reached €2.4 million as of December 31, 2025, increasing from €0.6 million at the end of September due to a partial capital increase.

• Additional €2.9 million fundraising closed on January 7, 2026, with €0.7 million used to repay convertible bonds.

• Net working capital is sufficient to meet obligations through February 2026, with expected revenues from early access programs to support operations through the year.

Financial highlights

• Cash position improved to €2.4 million at year-end 2025, up from €0.6 million at September 30, 2025.

• After fundraising and bond repayment, cash and cash equivalents totaled €2.9 million as of January 7, 2026.

Outlook and guidance

• Revenues from compassionate access programs in France and Israel are expected to ensure operational continuity through 2026.

• Ongoing funding operations, both dilutive and non-dilutive, are planned to extend the cash runway and finance the RECOVER Phase III trial.